Form 8-K - Current report:
SEC Accession No. 0000950170-25-038879
Filing Date
2025-03-13
Accepted
2025-03-13 17:14:07
Documents
15
Period of Report
2025-03-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K stro-20250313.htm   iXBRL 8-K 70560
2 EX-99.1 stro-ex99_1.htm EX-99.1 196413
3 EX-99.2 stro-ex99_2.htm EX-99.2 48322
4 GRAPHIC img217863751_0.jpg GRAPHIC 9954
5 GRAPHIC img218787272_0.jpg GRAPHIC 5459
  Complete submission text file 0000950170-25-038879.txt   474752

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT stro-20250313.xsd EX-101.SCH 26372
17 EXTRACTED XBRL INSTANCE DOCUMENT stro-20250313_htm.xml XML 4527
Mailing Address 111 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 111 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 650-392-8412
SUTRO BIOPHARMA, INC. (Filer) CIK: 0001382101 (see all company filings)

IRS No.: 452441988 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38662 | Film No.: 25736814
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)